Conference Coverage
Conference Coverage
Ozanimod for relapsing MS shows long-term safety, efficacy with age differences
Urinary tract infections and other treatment-emergent adverse events increased with age, but respiratory infections were more common among...
Conference Coverage
Multiple changes in NMOSD treatment for nonmedical reasons tied to poorer outcomes
“Our data highlight that aspects outside of therapeutic efficacy may be remarkably meaningful in the effective suppression of disease advancement...
Conference Coverage
Racial, ethnic disparities persist in access to MS care
Hispanic patients were significantly more likely to consistently report lower access to MS-specific care and feeling less heard by their health...
Conference Coverage
Long-term freedom from NMOSD relapse with satralizumab
At week 240 (4.6 years), 72% of satralizumab-treated patients were relapse-free, with 91% free from severe relapse.
Conference Coverage
Mindfulness-based stress reduction program benefits MS patients
Two separate programs showed significant improvements in participants’ stress, depressive and anxiety symptoms, self-awareness, and self-efficacy...
Conference Coverage
Oral drug for brain tumor could change treatment landscape
Vorasidenib was associated with a significant delay in time to disease progression when compared with placebo, in a new study.
Conference Coverage
Preventive antipyretics, antibiotics not needed in stroke
“Remarkably, neither ceftriaxone nor metoclopramide had any effect on the risk of developing pneumonia. It was all quite disappointing.”
Conference Coverage
Intensive BP reduction after stroke recanalization harmful
The results suggest, “despite recanalization, some areas in the ischemic brain may have already been damaged,” or that surrounding areas continue...
Conference Coverage
Tenecteplase late after stroke misses endpoint: TIMELESS
“The most encouraging observation was that we did not show any safety issues with giving TNK to this population at such a late time.”
Conference Coverage
Cardiopathy no basis for choosing anticoagulation in ESUS
“It could be that this concept of thrombogenic atrial cardiopathy really isn’t present unless there is also atrial fibrillation.”
Conference Coverage
No added benefit from revascularization in low-risk CAS
“We are more aware of how we should treat” these patients, and “we’re probably a bit more aggressive,” which will have shifted the outcomes in the...